Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) has announced the UK launch of Beclu® (beclometasone dipropionate) 100 micrograms (mcg) and 200 mcg pressurised metered dose inhalers (pMDI) for the treatment of mild, moderate or severe asthma. Beclu 100 is indicated for both adults and children, while Beclu 200mcg is indicated for adult use only.
The availability of Beclu pMDIs has the potential to provide cost savings for the NHS whilst being a certified carbon neutral inhaler as a result of carbon offsetting.
Beclu 100 and 200 have the same active ingredients and licensed indications as the respective strengths of Clenil® Modulite® and Soprobec®. All Beclu inhalers include a dose indicator enabling patients to quickly and easily monitor their medication use.
Approximately 5.4 million people are currently receiving treatment for asthma in the UK, which is equivalent to one in every 12 adults and one in every 11 children. The annual asthma cost burden on the NHS is estimated at £3 billion per year.
Over the past 12 months, to February 2023, the NHS spent over £43 million on Clenil® Modulite® 100 and 200mcg. Beclu pMDIs offer a 30% NHS list price saving vs Clenil® Modulite® 100 and 200mcg, equating to approximately £13 million per annum for the NHS.
Following an independent Life Cycle Assessment (LCA) by Carbon Footprint Ltd to calculate the carbon footprint of Beclu pMDIs, Lupin Healthcare will offset the carbon footprint of all Beclu 100 and 200 pMDIs sold in the UK. Through this process Beclu pMDIs are the only certified carbon neutral beclometasone dipropionate pMDIs available in the UK market.
“This additional pMDI launch demonstrates Lupin’s commitment to respiratory and to delivering value to the NHS. Whilst carbon reduction is core to our long-term carbon reduction plan, providing this carbon neutral product we believe demonstrates our environmental commitments,” said Ben Ellis, General Manager – Lupin Healthcare UK.
